Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients

Yizhen Liu, Kai Xue, Zuguang Xia, Jia Jin, Jiachen Wang, Hui Sun, Fangfang Lv, Xiaojian Liu, Junning Cao, Xiaonan Hong, Ye Guo, Xuejun Ma, Qunling Zhang, Yizhen Liu, Kai Xue, Zuguang Xia, Jia Jin, Jiachen Wang, Hui Sun, Fangfang Lv, Xiaojian Liu, Junning Cao, Xiaonan Hong, Ye Guo, Xuejun Ma, Qunling Zhang

Abstract

Background: The optimal treatment strategies for extranodal natural killer/ T-cell lymphoma (ENKTL) have not been defined. We conducted this prospective, open-label, phase II, single-center study aimed to explore the efficacy and safety of radiotherapy followed by DICEP (Dexamethasone, ifosfamide, cisplatin, etoposide, and pegaspargase) regimen in the treatment of patients with untreated, stage IE/IIE, extranodal NK/T-cell lymphoma.

Methods: Thirty eligible patients were enrolled in this study, receiving radiotherapy of 50Gy/25fx, and followed by chemotherapy with DICEP regimen for 3 cycles if tolerated. Median follow-up time of this study was 70.8 months. We constructed Kaplan-Meier survival curves for survival analyses.

Results: The most common manifestations at the onset of disease were nasal obstruction (80%), with or without fever, and pharyngalgia (20%). The overall response rate (ORR) was 96.7% (29/30). Four patients (13.3%) had progression of the disease (PD), the estimated 5-year progression-free survival (PFS) rate was 86%. Four patients (13.3%) died of disease, and the estimated 5-year cumulative overall survival (OS) was 87%. The most common hematological toxicity was grade 3 or grade 4 neutropenia, which could be successfully managed via using growth-stimulating factors or dose modifications. Hypoalbuminemia and decreased fibrinogen are the top two nonhematologic toxicities. No treatment-related death occurred in this study.

Conclusions: Our present study showed that radiotherapy followed by DICEP chemotherapy could be an effective and tolerable treatment modality for newly diagnosed, stage IE/IIE ENKTL patients. Adverse events were predictable and manageable.

Trial registration: ClinicalTrials.gov Identifier: NCT01667302. Registered: 1 July 2012.

Keywords: DICE; NK/T-cell lymphoma; Pegaspargase; radiation.

© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
PFS and OS of NK/T patients in our study The PFS (left) and OS (right) of stage IE/IIE NK/T patients in our study

References

    1. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T‐cell lymphoma: a study of 136 cases from the International Peripheral T‐Cell Lymphoma Project. Blood. 2009;113(17):3931‐3937.
    1. Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T‐cell lymphoma. Clin Cancer Res. 2009;15(8):2905‐2912.
    1. Lee J, Suh C, Park YH, et al. Extranodal natural killer T‐cell lymphoma, nasal‐type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612‐618.
    1. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long‐term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216‐221.
    1. Li YY, Feng LL, Niu SQ, et al. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase‐based chemotherapy. Oncotarget. 2017;8(7):11480‐11488.
    1. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P‐glycoprotein/MDR1 by nasal T‐cell lymphoma cells. Cancer. 1995;76(11):2351‐2356.
    1. Wang B, Lu JJ, Ma X, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T‐cell lymphoma of nasal cavity. Leuk Lymphoma. 2007;48(2):396‐402.
    1. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T‐cell lymphoma? Ann Oncol. 2001;12(3):349‐352.
    1. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T‐cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973‐2980.
    1. Wang L, Wang ZH, Chen XQ, et al. First‐line combination of gemcitabine, oxaliplatin, and L‐asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma. Cancer. 2013;119(2):348‐355.
    1. Jaccard A, Gachard N, Marin B, et al. Efficacy of L‐asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T‐cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834‐1839.
    1. Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary. 1995;30(7):388‐393.
    1. Escherich G, Zur Stadt U, Zimmermann M, Horstmann MA. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08‐09 trial. Br J Haematol. 2013;163(2):240‐247.
    1. Shen Q, Ma X, Hu W, et al. Intensity‐modulated radiotherapy versus three‐dimensional conformal radiotherapy for stage I‐II natural killer/T‐cell lymphoma nasal type: dosimetric and clinical results. Radiat Oncol. 2013;8:152.
    1. Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;19(6):894‐900.
    1. Tse E, Kwong YL. How I treat NK/T‐cell lymphomas. Blood. 2013;121(25):4997‐5005.
    1. Tsai HJ, Lin SF, Chen CC, et al. Long‐term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T‐cell lymphoma. Eur J Haematol. 2015;94(2):130‐137.
    1. Dong LH, Zhang LJ, Wang WJ, et al. Sequential DICE combined with l‐asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T‐cell lymphoma. Leuk Lymphoma. 2016;57(7):1600‐1606.
    1. Jing XM, Zhang ZH, Wu P, et al. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly‐diagnosed extranodal nature killer (NK)/T cell lymphoma. Leuk Res. 2016;47:26‐31.
    1. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T‐cell lymphoma. J Clin Oncol. 2006;24(1):181‐189.
    1. Chaudhary RK, Bhatt VR, Vose JM. Management of extranodal natural killer/t‐cell lymphoma, nasal type. Clin Lymphoma Myeloma Leuk. 2015;15(5):245‐252.
    1. Shi Y. Current status and progress of lymphoma management in China. Int J Hematol. 2018;107(4):405‐412.
    1. Makita S, Tobinai K. Clinical features and current optimal management of natural killer/T‐cell lymphoma. Hematol Oncol Clin North Am. 2017;31(2):239‐253.
    1. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L‐asparaginase‐containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08‐01 phase II study. Ann Hematol. 2014;93(11):1895‐1901.
    1. Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of "sandwich" L‐asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T‐cell lymphoma. Cancer. 2012;118(13):3294‐3301.
    1. Wang L, Wang ZH, Chen XQ, et al. First‐line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long‐term follow‐up. Oncol Lett. 2015;10(2):1036‐1040.
    1. Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T‐cell lymphoma. Ann Oncol. 2018;29(1):256‐263.
    1. Pokrovsky VS, Vinnikov D. Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion. Expert Rev Anticancer Ther. 2019;19(1):93‐104.
    1. Wei L, Wang J, Ye J, et al. Long‐term outcomes of patients treated with an EPOCHL regimen as first‐line chemotherapy for newly diagnosed extranodal natural killer/T‐cell lymphoma: a retrospective single‐center study. Leuk Lymphoma. 2020;61(2):337‐343.
    1. Hu Y, Chen M, Song Y, et al. Study of L‐asparaginase, vincristine, and dexamethasone combined with intensity‐modulated radiation therapy in early‐stage nasal NK/T‐cell lymphoma. Am J Clin Oncol. 2020;43(4):257‐262.
    1. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T‐Cell Lymphoma: consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27(35):6027‐6032.
    1. Ke QH, Zhou SQ, Du W, et al. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T‐Cell lymphoma. Blood Cancer J. 2014;4:e267.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel